MIRM · Mirum Pharmaceuticals, Inc.

Current Thesis

Mirum Pharmaceuticals’ rare-disease expansion story faces a 2026-09-26 regulatory decision after the market invalidated its published $100 recovery shelf. The adjusted close was $91.83 on 2026-09-18, below both that threshold and the $100.90 close recorded on 2026-09-04. The upcoming decision concerns zilurgisertib for fibrodysplasia ossificans progressiva (FOP), according to the companies’ 2026-06-14 announcement.

For the published momentum leg, the narrative is dead — the 2026-09-18 weekly close breached the existing $100 condition after September’s reclaim. This is an interpretation of the observed price structure, not a finding that the medicines have failed. The remaining fundamental case rests on commercial growth and clinical expansion; approval and statistically significant hepatitis delta results would establish evidence for a subsequent recovery thesis.

Bullish and bearish views on Mirum Pharmaceuticals, Inc.

The model's bull view on Mirum Pharmaceuticals, Inc. (MIRM), in brief: Commercial growth remains documented. Mirum’s 2026-08-05 results reported second-quarter net product sales of $176.2 million and raised full-year guidance to $680–700 million. LIVMARLI sales reached $128.7 million, up 46% year over year. These figures support the existing… The bear view: The primary endpoint qualifies enthusiasm. Both cases follow in full.

Bull Case

• Commercial growth remains documented. Mirum’s 2026-08-05 results reported second-quarter net product sales of $176.2 million and raised full-year guidance to $680–700 million. LIVMARLI sales reached $128.7 million, up 46% year over year. These figures support the existing franchise; a subsequent reduction below that guidance range would contradict continued commercial execution. Company results.

• Lesion-volume results support regulatory review. The 2026-06-14 PROGRESS release reported more than a 99% reduction in new abnormal bone-lesion volume, with a nominal p-value below 0.0001. This supports biological activity, but does not establish approval probability; an adverse regulatory decision would defeat the immediate expansion case. PROGRESS release.

• Hepatitis delta offers another test. Mirum’s 2026-04-27 AZURE-1 Phase 2b update reported combined virologic response and alanine aminotransferase (ALT) normalisation in 45% and 35% of the treatment groups. Those results support testing brelovitug in Phase 3; failure to establish statistical significance on the combined endpoint would contradict the proposed clinical expansion. The interim sample cannot establish the later trial’s outcome.

Bear Case

• The primary endpoint qualifies enthusiasm. The 2026-06-14 PROGRESS release reported p=0.0986 for the proportion of patients developing new lesions, which it identified as the primary endpoint. The much stronger lesion-volume result concerned a secondary endpoint with a nominal p-value. Earlier characterisation of the dataset as unusually clean omitted this distinction. PROGRESS release.

• Approved competition already exists. FDA records date Sohonos approval to 2023-08-16 and list Pasatru as the second FOP treatment on 2026-08-19. The earlier assertion that zilurgisertib would enter a market without an approved competitor was incorrect. These approvals establish competition; they do not establish future market shares. Sohonos approval record, FDA approval calendar.

• Losses accompany the sales expansion. Mirum reported a second-quarter net loss of $67.2 million on 2026-08-05, with research and development expense of $90.5 million and selling, general and administrative expense of $81.5 million. That balance alone does not establish a cash-runway duration. Company results.

Setup & Price Structure

The supplied adjusted daily series records a $91.83 close on Friday, 2026-09-18, a three-month price decline of 14.8%, and a price 28.6% below the $128.57 trailing-year high. The previously published $100 shelf has failed again. Retaining that threshold preserves the original test; substituting a lower number would conceal an already observed invalidation.

Attention was clustered before the decision: Mirum’s 2026-09-02 announcement scheduled five investor-conference appearances between 2026-09-09 and 2026-09-16. The subsequent September 18 close shows that the scheduled visibility did not coincide with retention of the $100 shelf. Conference scheduling measures exposure, not ownership or buying pressure.

Current fund-flow, short-interest and moving-average observations are missing from the supplied evidence. The conference cluster and price decline cannot establish crowded ownership, forced selling or the cause of the decline.

Catalyst Calendar (next 30 days)

• 2026-09-26 — Zilurgisertib regulatory decision. The companies’ 2026-06-14 release identifies this as the Food and Drug Administration’s Prescription Drug User Fee Act (PDUFA) target action date. Approval, a request for additional work, or a changed timetable would resolve different parts of the immediate regulatory case; the target date is not a guarantee of approval. Company announcement.

• ~2026-09-30 — AZURE-1 guidance checkpoint. The 2026-08-05 business update placed the Phase 3 hepatitis delta readout in the third quarter. September 30 marks the end of that guidance window, not a confirmed announcement appointment. Passage without topline results would invalidate the timing claim; statistical significance on the combined virologic-response and ALT-normalisation endpoint is the clinical test. Company business update.

What Would Change Our Mind

The September recovery shelf has already broken: a weekly close below $100 was the published thesis-break condition, and the 2026-09-18 close of $91.83 satisfies it. A later rebound cannot erase that outcome.

A subsequent recovery case would require a weekly close above the same $100 market shelf together with favourable regulatory or Phase 3 evidence. A renewed weekly close below $100 would invalidate that price recovery; a regulatory rejection or an AZURE-1 combined-endpoint failure would defeat the corresponding clinical leg. The 2026-06-14 PROGRESS endpoint distinction and the FDA’s 2026-08-19 competitor approval also mean that approval alone would not establish commercial differentiation.

Correlation Notes

This remains a single-name catalyst case as of 2026-09-20. No current theme cluster is supplied, and no paired return series supports a numerical correlation claim or attribution of the September decline to a sector move.

Incyte has a contractual connection: Mirum’s 2026-05-06 announcement disclosed exclusive worldwide zilurgisertib rights, with milestones and tiered royalties payable to Incyte. That establishes linked drug economics, not measured share-price correlation. License disclosure.